Changes in CArG-binding protein A expression levels following injection(s) of the D1-dopamine agonist SKF-82958 in the intact and 6-hydroxydopamine-lesioned rat.
We recently characterized the rat brain homolog of mouse muscle CArG-binding protein A initially identified in C2 myogenic cells and showed an inverse temporal correlation between increased expression levels of this messenger RNA, c-fos and zif268 messenger RNA levels following the addition of nerve growth factor to PC12 cells. In addition, we found an inverse correlation between c-Fos protein and CArG-binding protein A messenger RNA levels in the lateral caudate-putamen of rats treated acutely and chronically with the D2 receptor antagonist fluphenazine (phenothiozine typical psychotic). To determine whether D1 receptor stimulation is also capable of inducing CArG-binding protein A up-regulation, drug naive or dopamine-depleted (i.e. 6-hydroxydopamine-lesioned) D1 hypersensitized rats (i.e. rats given repeated daily injections of SKF-82958 for 14days) were acutely injected with the D1 agonist SKF-82958 and examined using a combination of in situ hybridization for CArG binding protein A and immunocytochemistry for c-Fos. Both acutely treated animals and dopamine-depleted hypersensitized animals showed increases in CArG-binding protein A. Moderate increases were found in the medial caudate-putamen and nucleus accumbens core and shell regions following acute treatment whereas large increases in CArG-binding protein A expression levels were found in the medial and lateral caudate-putamen and the shell and core of the nucleus accumbens following hypersensitization. No change in CArG-binding protein A expression level was found in the dopamine-depleted, drug naive animals relative to controls. Regions of the basal ganglia where increases in CArG-binding protein A were detected following each treatment correlated perfectly with c-Fos protein induction. The results demonstrate that CArG-binding protein A responds to SKF-82958 and that the changes in CArG-binding protein A match perfectly with the pattern of c-Fos induction induced by the D1 agonist.
Rushlow
W J
WJ
Department of Anatomy and Cell Biology, The University of Western Ontario, Ontario, London, Canada. wrushlow@julian.uwo.ca
Rajakumar
B
B
Flumerfelt
B A
BA
Naus
C C
CC
Rajakumar
N
N
D000818:Animals; D001552:Benzazepines / Q000494:pharmacology*; D018797:Cell Cycle Proteins; D003342:Corpus Striatum / Q000737:chemistry / Q000502:physiology; D004268:DNA-Binding Proteins / Q000235:genetics*; D003714:Denervation; D018491:Dopamine Agonists / Q000494:pharmacology*; D015870:Gene Expression / Q000187:drug effects; D017781:Genes, Immediate-Early / Q000502:physiology; D034481:Heterogeneous-Nuclear Ribonucleoprotein Group A-B; D017403:In Situ Hybridization; D008297:Male; D016627:Oxidopamine; D016760:Proto-Oncogene Proteins c-fos / Q000032:analysis / Q000235:genetics; D012333:RNA, Messenger / Q000032:analysis; D051381:Rats; D017207:Rats, Sprague-Dawley; D017447:Receptors, Dopamine D1 / Q000819:agonists*; D012097:Repressor Proteins / Q000235:genetics*; D012261:Ribonucleoproteins; D013565:Sympatholytics; D014157:Transcription Factors
D001552:Benzazepines; D018797:Cell Cycle Proteins; D004268:DNA-Binding Proteins; D018491:Dopamine Agonists; D034481:Heterogeneous-Nuclear Ribonucleoprotein Group A-B; C121363:Hnrnpab protein, rat; D016760:Proto-Oncogene Proteins c-fos; D012333:RNA, Messenger; D017447:Receptors, Dopamine D1; D012097:Repressor Proteins; D012261:Ribonucleoproteins; D013565:Sympatholytics; D014157:Transcription Factors; C071262:SK&F 82958; D016627:Oxidopamine